Air deodorant for critical care room and preparation method of air deodorant

Abstract

The invention discloses an air deodorant for a critical care room and a preparation method of the air deodorant, and belongs to the field of deodorants. The component A is a solid adsorption carrier, the component B is a capsule treating agent, and the component B is uniformly distributed on the component A; the component A comprises the following components in parts by weight: 100 parts of graphene modified activated carbon, 50 parts of a molecular sieve and 5-6 parts of a silane coupling agent; a shell of a capsule in the component B is prepared from the following components in parts by weight: 50 to 52 parts of beewax, 30 parts of glycerin monostearate, 10 parts of polar modified polyethylene and 3 to 4 parts of nano metal oxide; the inner core of the capsule comprises the following components in parts by weight: 60-70 parts of a short-chain compound esterified and modified yucca extract, 80 parts of a volatile solvent, 10 parts of propylene glycol, 5 parts of essence and 15 parts of xanthan gum. The deodorization component taking the yucca extract as a main component can be partially volatilized into the air and reacts with ammonia gas, hydrogen sulfide and other substances in the air, and the deodorization effect is achieved.

Description

Technical Field

[0001] The invention belongs to the field of deodorants, and relates to an air deodorant for an intensive care room and a preparation method thereof. Background Art

[0002] Most of the patients in the intensive care unit are critically ill or seriously ill and cannot control their own excretion; therefore, the air in the intensive care unit not only smells like disinfectant and blood, but also has an obvious odor of excrement; in order to ensure that the intensive care unit has clean air, deodorants are often used to remove the odor in the intensive care unit; the commonly used deodorant is activated carbon, which is a solid deodorant that will not adhere to equipment or patients in large quantities and is safer to use than spray deodorants; however, the deodorization efficiency of activated carbon deodorants is low and adsorption saturation is quickly reached. Summary of the invention

[0003] The purpose of the present invention is to provide an air deodorant for an intensive care unit and a preparation method thereof, so as to solve the problems of low deodorization efficiency and short use time of the existing activated carbon deodorant in the intensive care unit.

[0004] The technical solution adopted by the present invention is as follows: An air deodorizer for an intensive care room, comprising component A and component B, wherein the mass ratio of component A to component B is 1:1.7-2; the component A is a solid adsorption carrier, the component B is a capsule treatment agent, and the component B is evenly distributed on the component A; The component A comprises the following components in parts by weight: 100 parts of graphene-modified activated carbon, 50 parts of molecular sieve, and 5-6 parts of silane coupling agent; The shell of the capsule in component B comprises the following components in parts by weight: 50-52 parts of beeswax, 30 parts of glyceryl monostearate, 10 parts of polar-modified polyethylene, and 3-4 parts of nano-metal oxides; the inner core of the capsule comprises the following components in parts by weight: 60-70 parts of yucca extract modified by esterification of short-chain compounds, 80 parts of volatile solvents, 10 parts of propylene glycol, 5 parts of flavors, and 15 parts of xanthan gum.

[0005] The present application provides an air deodorizer for use in a 50°C heating environment. In a thermal environment of about 50°C, the deodorizing component with yucca extract as the main ingredient can partially volatilize into the air, reacting with ammonia, hydrogen sulfide and other substances in the air, thereby reducing the concentration of odorous substances such as ammonia and hydrogen sulfide in the air, thereby playing a role in volatilization and deodorization.

[0006] Yucca extract itself is a substance that is not easy to volatilize. In order to improve the volatility of yucca extract, the present invention uses short-chain compounds to esterify the yucca extract and mixes the modified yucca extract with a volatile solvent. On the one hand, through the esterification reaction, the macromolecular compounds in the yucca extract are converted into small molecular esters. These small molecular esters have a lower boiling point and are easier to evaporate, thereby improving the overall volatility; on the other hand, the rapid volatilization of the volatile solvent can carry the yucca extract to evaporate quickly, further improving the volatilization rate of the yucca extract; After the volatility of yucca extract increases, its stability becomes worse and it is not easy to store. Therefore, the present application uses the yucca extract modified by esterification of short-chain compounds and the treatment agent with volatile solvent as the main components as the core material, and cooperates with the shell material to prepare a capsule structure. The capsule shell cuts off the contact between the core material and the outside world, which can effectively prevent the yucca extract modified by esterification of short-chain compounds, volatile solvents, etc. from escaping during storage, thereby improving the storage stability of the treatment agent; The shell of the treatment agent capsule in the present invention is mainly composed of beeswax, which will melt quickly under heating conditions to release the inner core material, and will not significantly reduce the deodorization efficiency of the core material; however, the surface of beeswax is smooth and has low polarity after solidification, making it difficult to firmly adhere to the carrier, and it also has low mechanical strength and poor thermal conductivity, which affects the thermal response and stability of the capsule shell. Therefore, the present invention adds monostearate, polar-modified polyethylene, and nano-metal oxide to beeswax; on the one hand, monostearate can jointly adjust the melting point of the capsule shell with beeswax, so that the capsule shell can melt quickly at a temperature of about 50°C, and on the other hand, monostearate can also enhance the viscosity between the capsule shell and the carrier. Monostearate is a nonionic surfactant, and its molecules contain polar groups and non-polar groups. The polar groups can form hydrogen bonds with the surface of the carrier, thereby improving the adhesion between the capsule shell and the carrier. Adhesion of the carrier; non-polar groups are compatible with beeswax, improving the surface wettability of beeswax and making it easier to adhere to the surface of the carrier; polar modified polyethylene is mainly used to improve the mechanical strength of the capsule shell; nano metal oxides are used to improve the thermal conductivity and mechanical strength of the capsule shell; beeswax has poor compatibility with polar modified polyethylene and nano metal oxides, and glyceryl monostearate can reduce the interfacial tension between beeswax and other components and promote uniform mixing; polyethylene has a high melting point, and its melting point can be reduced by polar modification so that it does not affect the melting point of the capsule shell; if the melting point of the capsule shell is too high, a higher temperature is required to melt it, but high temperature will not only make the kernel material evaporate quickly in a short time, increase the amount of kernel material used, and shorten the continuous deodorization time; and higher temperatures will not only significantly increase the temperature inside the intensive care unit, but the indoor temperature of the intensive care unit cannot be too high, and too high a temperature will affect the patient's condition. The present invention combines the overall deodorization efficiency of the deodorant, the continuous deodorization time and the temperature effect on the indoor intensive care unit, and limits the use temperature of the deodorant of this application to about 50 ° C.

[0007] The present invention modifies the activated carbon so that it has a good heat conduction effect, and cooperates with the capsule wall having a heat conduction effect to enhance the thermal response of the capsule wall.

[0008] After the capsule wall melts, the inner core material is released, which performs volatilization deodorization on the one hand; on the other hand, the liquid material is adsorbed on the solid carrier, the solid carrier adsorbs the odorous substances, and the liquid material decomposes the odorous substances, which can improve the deodorization effect and the adsorption saturation of the activated carbon and increase the service life of the activated carbon. The combination of volatilization deodorization and adsorption deodorization has high deodorization efficiency and good effect.

[0009] Furthermore, the short-chain compound esterified modified yucca extract is prepared by the following method: A1. Protecting active hydroxyl groups: dissolving the yucca extract in anhydrous pyridine, adding tert-butyldimethylsilyl chloride and 4-dimethylaminopyridine, stirring and reacting at room temperature for 12 hours, and after the reaction, purifying by column chromatography, eluting with an eluent, collecting fractions containing the protected yucca extract, and concentrating to obtain the protected yucca extract; wherein the ratio of the yucca extract to anhydrous pyridine is 1:10 g / ml, the mass ratio of tert-butyldimethylsilyl chloride to the yucca extract is 1.5:1, and the amount of 4-dimethylaminopyridine added is 5% of the mass of the yucca extract; B1. Esterification reaction: the protected yucca extract is mixed with glacial acetic acid and a small amount of concentrated sulfuric acid, heated and stirred in a 50°C oil bath for 6 hours and then cooled. After cooling, a saturated sodium carbonate solution is added to neutralize the excess acid until the solution is neutral; then extracted with ethyl acetate, the organic phase and the aqueous phase are separated, the organic phase is collected, dried with anhydrous sodium sulfate, filtered and concentrated to obtain a crude product; wherein the ratio of yucca extract to glacial acetic acid is 1:5 g / ml, and the ratio of yucca extract to concentrated sulfuric acid is 1:0.25 g / ml; C1. Deprotection: The crude product is dissolved in dichloromethane, tetrabutylammonium fluoride is added, and the mixture is stirred at room temperature for 4-6 hours. After the reaction is completed, the mixture is purified by column chromatography, and an eluent is used to elute the mixture, and the fractions containing the esterified modified yucca extract are collected and concentrated to obtain the esterified modified yucca extract of the short-chain compound; wherein the mass ratio of tetrabutylammonium fluoride to the crude product is 1.5:1.

[0010] In the esterification process, the activity is protected to improve the volatility of the yucca extract without affecting the activity.

[0011] Furthermore, the graphene-modified activated carbon is prepared by the following method: A2, adding graphene oxide powder to deionized water to prepare a dispersion of 1-5 mg / mL, and then ultrasonically treating for 60 minutes to obtain a graphene oxide dispersion; B2. Wash the activated carbon with deionized water and ethanol alternately and dry it at 60-80°C for later use; C2, adding the dried activated carbon to the graphene oxide dispersion, stirring and mixing, using ultrasonic treatment for 30 minutes and then standing for 12 hours, then filtering, washing and drying to obtain graphene oxide-coated activated carbon; D2, placing the activated carbon coated with graphene oxide in a tube furnace, introducing an inert gas, wherein the inert gas is N2 or Ar, excluding air, maintaining an inert atmosphere, heating to 900°C at a heating rate of 5-10°C / min, maintaining at 900°C for 1 hour, and naturally cooling to room temperature to obtain graphene-modified activated carbon; Wherein, in step C2, the mass ratio of graphene oxide to activated carbon is 1:10.

[0012] Furthermore, the volatile solvent includes ethyl acetate and ethanol, and the mass ratio of ethyl acetate to ethanol is 1:2.

[0013] Furthermore, the capsule shell in the component B also includes 20-22 parts of acrylic acid-modified poly-N-isopropylacrylamide, and the preparation method of the acrylic acid-modified poly-N-isopropylacrylamide is as follows: A3, dissolving N-isopropylacrylamide and acrylic acid in deionized water at a mass ratio of 9:1 to prepare a monomer solution; B3. Under stirring and heating, add 1% of ammonium persulfate by weight of the total monomer to the monomer solution, heat to 50°C and react for 1 hour, then add 0.5% of N,N'-methylenebisacrylamide by weight of the total monomer, heat to 60°C under nitrogen protection and react for 6 hours. After the reaction, purify and dry to obtain acrylic acid-modified poly (N-isopropylacrylamide).

[0014] The acrylic acid-modified poly N-isopropylacrylamide is in a gel state within 50°C. After cross-linking reaction with other components of the capsule shell, the prepared capsule shell has good flexibility, which is beneficial to improving the flexibility of the capsule, reducing the brittleness of the capsule, and making it stable in use. In addition, the acrylic acid-modified poly N-isopropylacrylamide is temperature-sensitive. When the capsule shell melts, the acrylic acid-modified poly N-isopropylacrylamide is released to form a gel-like substance. The gel-like substance will enhance the adhesion of the core substance on the solid carrier, so that the core substance can be heated evenly. When the temperature is higher than 50°C, the molecular chain of the acrylic acid-modified poly N-isopropylacrylamide dehydrates and shrinks to form a hydrophobic aggregation state, and the structure becomes hard, which will lock part of the core substance on the solid carrier. Compared with the component without adding acrylic acid-modified poly N-isopropylacrylamide, the volatilization speed of the core substance at the current temperature is reduced, and the core substance is prevented from volatilizing completely in a short time. At this time, the odorous substance can be mainly adsorbed in the solid carrier by relying on the solid carrier, and then the odorous substance is decomposed by the core substance on the solid carrier to carry out deodorization treatment.

[0015] Furthermore, the nano metal oxide in the component B includes nano zinc oxide and nano aluminum oxide, and the mass ratio of nano zinc oxide to nano aluminum oxide is 1:3.

[0016] Furthermore, the molecular sieves in the component A include MCM-41 mesoporous molecular sieve, 13X zeolite molecular sieve, and Beta zeolite, and the mass ratio of MCM-41 mesoporous molecular sieve, 13X zeolite molecular sieve, and Beta zeolite is 1:2:1.

[0017] Furthermore, the polar modified polyethylene is a low-density linear polyethylene grafted with maleic anhydride.

[0018] Furthermore, the component B is prepared by the following method: A4, adding beeswax, glyceryl monostearate and polar modified polyethylene into a reaction kettle, heating to 70-80° C., and stirring until completely melted to obtain a first intermediate; B4, adding nano metal oxide to the first intermediate, stirring evenly, to obtain a second intermediate; C4, dissolving acrylic acid-modified poly-N-isopropylacrylamide in an appropriate amount of deionized water, then adding N,N'-methylenebisacrylamide and ammonium persulfate, stirring evenly, adding the second intermediate, stirring evenly, heating to 70°C, reacting for 2 hours, cooling to 40°C after the reaction, keeping the liquid state, and obtaining a capsule shell material for standby use; wherein, the amount of N,N'-methylenebisacrylamide added is 0.5% of the mass of acrylic acid-modified poly-N-isopropylacrylamide, and the amount of ammonium persulfate added is 0.5% of the mass of acrylic acid-modified poly-N-isopropylacrylamide; D4, dissolving the yucca extract modified by esterification of short-chain compounds in a volatile solvent, adding propylene glycol, flavor and xanthan gum, and stirring evenly to form a uniform core solution; E4. Slowly add the inner core solution into the liquid capsule shell material, add an emulsifier, and emulsify using a high-speed shear emulsifier. During the emulsification process, the temperature is maintained at 50° C. After the emulsification is completed, cool at room temperature to obtain component B.

[0019] The method for preparing an air deodorant for an intensive care room comprises the following steps: S1. Prepare component A: activate the molecular sieve at 200-300° C. for 2-3 hours to remove moisture and impurities; dissolve the silane coupling agent in ethanol and stir evenly to obtain a silane coupling agent solution; prepare graphene-modified activated carbon, and then mix the graphene-modified activated carbon, the activated molecular sieve and the silane coupling agent solution, stir evenly, and dry at 60-80° C. to obtain component A; S2. preparing component B using capsule preparation technology; S3. Spray the prepared component B evenly on component A, stir and mix evenly, and then air-dry at room temperature for 2-3 hours to obtain the final air deodorant.

[0020] In summary, due to the adoption of the above technical solution, the beneficial effects of the present invention are: 1. The air deodorizer for intensive care rooms of the present invention uses the modified yucca extract as a treatment agent, which significantly improves the volatility of the yucca extract. Under heating conditions, it can not only rely on the polarity of the volatilized treatment agent for deodorization, but also rely on the synergistic effect of activated carbon, molecular sieve and yucca extract for deodorization, achieving double deodorization with high efficiency; 2. In the process of esterification modification of the yucca extract, the present invention protects the activity, thereby improving the volatility of the yucca extract without affecting its activity; 3. The present invention prepares the treatment agent into a capsule structure, which is conducive to the storage of volatile internal substances; 4. The present invention adds acrylic acid-modified poly N-isopropylacrylamide to the capsule shell. When the temperature of the deodorant reaches the applicable temperature, the acrylic acid-modified poly N-isopropylacrylamide will lock part of the core material, reduce the volatilization speed of the core material at the current temperature, avoid the core material from volatilizing in large quantities in a short time, and have the performance of preventing high temperature loss. DETAILED DESCRIPTION

[0021] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention, that is, the embodiments described are only part of the embodiments of the present invention, rather than all the embodiments. The components of the embodiments of the present invention described and shown herein can be arranged and designed in various different configurations.

[0022] Therefore, the detailed description of the embodiments of the present invention provided below is not intended to limit the scope of the invention claimed for protection, but merely represents selected embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without making creative work are within the scope of protection of the present invention.

[0023] It should be noted that relational terms such as "first" and "second" are used only to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device. In the absence of further restrictions, the elements defined by the sentence "comprise a ..." do not exclude the existence of other identical elements in the process, method, article or device including the elements.

[0024] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0025] Example 1 A preferred embodiment of the present invention provides an air deodorant for an intensive care room, comprising component A and component B, wherein the mass ratio of component A to component B is 1:1.7; component A is a solid adsorption carrier, and component B is a capsule treatment agent, and component B is evenly distributed on component A; The component A comprises the following components in parts by weight: 100 parts of graphene-modified activated carbon, 50 parts of molecular sieve, and 5-6 parts of silane coupling agent; The shell of the capsule in component B comprises the following components in parts by weight: 50-52 parts of beeswax, 30 parts of glyceryl monostearate, 10 parts of polar-modified polyethylene, and 3-4 parts of nano-metal oxides; the inner core of the capsule comprises the following components in parts by weight: 60-70 parts of yucca extract modified by esterification of short-chain compounds, 80 parts of volatile solvents, 10 parts of propylene glycol, 5 parts of flavors, and 15 parts of xanthan gum.

[0026] The short-chain compound esterified modified yucca extract is prepared by the following method: A1. Protecting active hydroxyl groups: dissolving the yucca extract in anhydrous pyridine, adding tert-butyldimethylsilyl chloride and 4-dimethylaminopyridine, stirring and reacting at room temperature for 12 hours, and after the reaction, purifying by column chromatography, eluting with an eluent, collecting fractions containing the protected yucca extract, and concentrating to obtain the protected yucca extract; wherein the ratio of the yucca extract to anhydrous pyridine is 1:10 g / ml, the mass ratio of tert-butyldimethylsilyl chloride to the yucca extract is 1.5:1, and the amount of 4-dimethylaminopyridine added is 5% of the mass of the yucca extract; B1. Esterification reaction: the protected yucca extract is mixed with glacial acetic acid and a small amount of concentrated sulfuric acid, heated and stirred in a 50°C oil bath for 6 hours and then cooled. After cooling, a saturated sodium carbonate solution is added to neutralize the excess acid until the solution is neutral; then extracted with ethyl acetate, the organic phase and the aqueous phase are separated, the organic phase is collected, dried with anhydrous sodium sulfate, filtered and concentrated to obtain a crude product; wherein the ratio of yucca extract to glacial acetic acid is 1:5 g / ml, and the ratio of yucca extract to concentrated sulfuric acid is 1:0.25 g / ml; C1. Deprotection: The crude product is dissolved in dichloromethane, tetrabutylammonium fluoride is added, and the mixture is stirred at room temperature for 4-6 hours. After the reaction is completed, the mixture is purified by column chromatography, and an eluent is used to elute the mixture, and the fractions containing the esterified modified yucca extract are collected and concentrated to obtain the esterified modified yucca extract of the short-chain compound; wherein the mass ratio of tetrabutylammonium fluoride to the crude product is 1.5:1.

[0027] The graphene-modified activated carbon is prepared by the following method: A2, adding graphene oxide powder to deionized water to prepare a dispersion of 5 mg / mL, and then subjecting the mixture to ultrasonic treatment for 60 minutes to obtain a graphene oxide dispersion; B2. Wash the activated carbon with deionized water and ethanol alternately and dry it at 60-80°C for later use; C2, adding the dried activated carbon to the graphene oxide dispersion, stirring and mixing, using ultrasonic treatment for 30 minutes and then standing for 12 hours, then filtering, washing and drying to obtain graphene oxide-coated activated carbon; D2, placing the activated carbon coated with graphene oxide in a tube furnace, introducing an inert gas, wherein the inert gas is N2 or Ar, excluding air, maintaining an inert atmosphere, heating to 900°C at a heating rate of 5-10°C / min, maintaining at 900°C for 1 hour, and naturally cooling to room temperature to obtain graphene-modified activated carbon; Wherein, in step C2, the mass ratio of graphene oxide to activated carbon is 1:10.

[0028] The volatile solvent includes ethyl acetate and ethanol, and the mass ratio of ethyl acetate to ethanol is 1:2.

[0029] The molecular sieves in the component A include MCM-41 mesoporous molecular sieve, 13X zeolite molecular sieve and Beta zeolite, and the mass ratio of MCM-41 mesoporous molecular sieve, 13X zeolite molecular sieve and Beta zeolite is 1:2:1.

[0030] The polar modified polyethylene is a low-density linear polyethylene grafted with maleic anhydride.

[0031] The component B is prepared by the following method: A4, adding beeswax, glyceryl monostearate and polar modified polyethylene into a reaction kettle, heating to 70-80° C., and stirring until completely melted to obtain a first intermediate; B4, adding nano metal oxide to the first intermediate, stirring evenly, to obtain a liquid capsule shell material; C4, dissolving the yucca extract modified by esterification of short-chain compounds in a volatile solvent, adding propylene glycol, flavor and xanthan gum, and stirring evenly to form a uniform core solution; D4. Slowly add the inner core solution into the liquid capsule shell material, add an emulsifier, and emulsify using a high-speed shear emulsifier. During the emulsification process, the temperature is maintained at 50° C. After the emulsification is completed, cool at room temperature to obtain component B.

[0032] The method for preparing an air deodorant for an intensive care room comprises the following steps: S1. Prepare component A: activate the molecular sieve at 200-300° C. for 2-3 hours to remove moisture and impurities; dissolve the silane coupling agent in ethanol and stir evenly to obtain a silane coupling agent solution; prepare graphene-modified activated carbon, and then mix the graphene-modified activated carbon, the activated molecular sieve and the silane coupling agent solution, stir evenly, and dry at 60-80° C. to obtain component A; S2. preparing component B using capsule preparation technology; S3. Spray the prepared component B evenly on component A, stir and mix evenly, and then air-dry at room temperature for 2-3 hours to obtain the final air deodorant.

[0033] Example 2 In this embodiment, based on the embodiment 1, the capsule shell in the component B further comprises 20-22 parts of acrylic acid-modified poly-N-isopropylacrylamide, and the preparation method of the acrylic acid-modified poly-N-isopropylacrylamide is as follows: A3, dissolving N-isopropylacrylamide and acrylic acid in deionized water at a mass ratio of 9:1 to prepare a monomer solution; B3. Under stirring and heating, add 1% of ammonium persulfate by weight of the total monomer to the monomer solution, heat to 50°C and react for 1 hour, then add 0.5% of N,N'-methylenebisacrylamide by weight of the total monomer, heat to 60°C under nitrogen protection and react for 6 hours. After the reaction, purify and dry to obtain acrylic acid-modified poly (N-isopropylacrylamide).

[0034] The nano metal oxide in the component B includes nano zinc oxide and nano aluminum oxide, and the mass ratio of nano zinc oxide to nano aluminum oxide is 1:3.

[0035] The component B is prepared by the following method: A4, adding beeswax, glyceryl monostearate and polar modified polyethylene into a reaction kettle, heating to 70-80° C., and stirring until completely melted to obtain a first intermediate; B4, adding nano metal oxide to the first intermediate, stirring evenly, to obtain a second intermediate; C4, dissolving acrylic acid-modified poly-N-isopropylacrylamide in an appropriate amount of deionized water, then adding N,N'-methylenebisacrylamide and ammonium persulfate, stirring evenly, adding the second intermediate, stirring evenly, heating to 70°C, reacting for 2 hours, cooling to 40°C after the reaction, keeping the liquid state, and obtaining a capsule shell material for standby use; wherein, the amount of N,N'-methylenebisacrylamide added is 0.5% of the mass of acrylic acid-modified poly-N-isopropylacrylamide, and the amount of ammonium persulfate added is 0.5% of the mass of acrylic acid-modified poly-N-isopropylacrylamide; D4, dissolving the yucca extract modified by esterification of short-chain compounds in a volatile solvent, adding propylene glycol, flavor and xanthan gum, and stirring evenly to form a uniform core solution; E4. Slowly add the inner core solution into the liquid capsule shell material, add an emulsifier, and emulsify using a high-speed shear emulsifier. During the emulsification process, the temperature is maintained at 50° C. After the emulsification is completed, cool at room temperature to obtain component B.

[0036] Example 3 This embodiment is based on Embodiment 2, but differs from Embodiment 2 in that the mass ratio of component A to component B is 1:1.8.

[0037] Example 4 This embodiment is based on Embodiment 2, but is different from Embodiment 2 in that the mass ratio of component A to component B is 1:2.

[0038] Comparative Example 1 This embodiment is based on Embodiment 2, but differs from Embodiment 2 in that the mass ratio of component A to component B is 1:1.6.

[0039] Comparative Example 2 This embodiment is based on Embodiment 2, but differs from Embodiment 2 in that the mass ratio of component A to component B is 1:2.1.

[0040] Comparative Example 3 This embodiment is based on the embodiment 2, but different from the embodiment 2 in that the outer shell of the capsule in component B includes 20-22 parts of poly (N-isopropylacrylamide) but does not include poly (N-isopropylacrylamide) modified by acrylic acid.

[0041] Comparative Example 4 This embodiment is based on Embodiment 2, but is different from Embodiment 2 in that component A does not include graphene-modified activated carbon.

[0042] Comparative Example 5 This embodiment is based on the embodiment 2, but is different from the embodiment 2 in that component A does not include molecular sieve.

[0043] Comparative Example 6 This embodiment is based on Embodiment 2, but is different from Embodiment 2 in that the activated carbon in Component A is not modified with graphene.

[0044] Comparative Example 7 This embodiment is based on Embodiment 1, but differs from Embodiment 1 in that component B consists only of a core material, including 60-70 parts of yucca extract modified by esterification of short-chain compounds, 80 parts of volatile solvents, 10 parts of propylene glycol, 5 parts of flavors, and 15 parts of xanthan gum; the core material is directly sprayed on component A to form a deodorant, and component B is not a capsule structure.

[0045] Comparative Example 8 This embodiment is based on the embodiment 2, but is different from the embodiment 2 in that the yucca extract in component B is not modified and is a conventional yucca extract.

[0046] Comparative Example 9 This embodiment is based on the embodiment 2, but different from the embodiment 2 in that glyceryl monostearate is not added to the shell of component B.

[0047] Comparative Example 10 This embodiment is based on the embodiment 2, but different from the embodiment 2 in that the polar modified polyethylene is not added to the outer shell of component B.

[0048] Comparative Example 11 This embodiment is based on the embodiment 2, but different from the embodiment 2 in that no nano metal oxide is added to the outer shell of component B.

[0049] Comparative Example 12 This embodiment is based on the embodiment 2, but different from the embodiment 2 in that the outer shell of component B uses unmodified polyethylene instead of polar modified polyethylene.

[0050] Comparative Example 13 This embodiment is based on Embodiment 2, but different from Embodiment 2 in that xanthan gum is not added to the inner core of Component B.

[0051] Comparative Example 14 This embodiment is based on the embodiment 2, but different from the embodiment 2 in that propylene glycol is not added into the inner core of component B.

[0052] Comparative Example 15 This example is based on Example 2, but different from Example 2 in that the deodorant in this comparative example only includes component A but does not include component B.

[0053] Comparative Example 16 This example is based on Example 2, but different from Example 2 in that the deodorant in this comparative example only includes component B but does not include component A.

[0054] Test Example 1 The deodorization efficiency of Examples 1-4 and Comparative Examples 1-16 was tested; The detection method of deodorization efficiency is as follows: taking ammonia and hydrogen sulfide as reference, detecting the concentrations of ammonia and hydrogen sulfide before and after treatment, deodorization efficiency = (concentration before treatment − concentration after treatment) / concentration before treatment × 100%; detection conditions: 100g component A, detection space 10m³, initial space temperature of 24℃, placed in a heating tank at 50℃, target odor substances: hydrogen sulfide (H2S) and ammonia (NH3), detection time 30 minutes, initial concentrations of hydrogen sulfide and ammonia are 10 ppm and 20 ppm respectively, multiple gas sampling points are set in the space to collect gas samples before and after treatment; multiple temperature detection points are set in the space at the same time, the initial temperature (24℃) before deodorization treatment and the final temperature after 30 minutes of deodorization are detected, the temperature change rate is detected, the values ​​of multiple detection points are calculated separately and the average value is taken, the temperature change rate = (final temperature − initial temperature) / initial temperature × 100%; the results are shown in Table 1.

[0055] Table 1 Deodorization efficiency and temperature change test results Hydrogen sulfide deodorization efficiency Ammonia deodorization efficiency Temperature change rate Example 1 ＞98% ＞95% ＜4% Example 2 ＞98% ＞95% ＜4% Example 3 ＞98% ＞95% ＜4% Example 4 ＞98% ＞95% ＜4% Comparative Example 1 96.8-97.1% 92.5-93% ＜4% Comparative Example 2 98.3-98.5% 95.3-95.9% ＜4% Comparative Example 3 96.7-97% 91-92.2% ＜4% Comparative Example 4 ＜70% ＜80% ＜4% Comparative Example 5 80-81% 84.5-85.1% ＜4% Comparative Example 6 79.6-81% 85.7-86.2% ＜4% Comparative Example 7 96.1-96.2% 90-91% ＜4% Comparative Example 8 ＜70% ＜70% ＜4% Comparative Example 9 96.8-97% 91-92% ＜4% Comparative Example 10 ＞98% ＞95% ＜4% Comparative Example 11 95.8-96.2% 91.1-92% ＜4% Comparative Example 12 ＜60% ＜70% ＜4% Comparative Example 13 96.8-97% 92.5-93% ＜4% Comparative Example 14 96.7-96.8% 93.1-93.5% ＜4% Comparative Example 15 58.5-58.6% 60.1-61.3% ＜4% Comparative Example 16 61.8-62.1% 64.2-64.5% ＜4% The deodorant in the present invention is used under the heating condition of 50°C. This use condition has little effect on the ambient temperature and can increase the ambient temperature, but the degree of increase is within 1°C, which will not cause much impact in the intensive care unit; the ammonia removal rate of the present invention under the above conditions reaches more than 95%, and the hydrogen sulfide removal rate reaches more than 98%, which has a significant deodorizing effect. In the present invention, the amount of component B is reduced, which will affect the deodorizing efficiency; however, if the amount of component B is too much, it will block component A, affect the adsorption of component A, and also affect the deodorizing efficiency. In the present invention, if the deodorant is volatilized into the air in a large amount in a short time, it will cause the local concentration to be too high, which not only wastes the deodorant, but also causes competition between deodorant molecules due to the high concentration, reducing the effective collision probability with odor molecules, thereby affecting the deodorizing efficiency, and a large amount of deodorant is volatilized in the air, and the smell of the deodorant will be too strong in the air, which will affect the freshness of the indoor air. The overly strong smell is easy to cause discomfort to indoor personnel.

[0056] Test Example 2 The moisture absorption and volatilization effects of component A in a dry environment are not obvious. Therefore, the weight change of component A in a dry environment within 30 minutes is very small and can be basically ignored. The volatilization of component B in the deodorants of Examples 1-4 and Comparative Examples 1-14 at different temperatures was tested, and the test temperatures were 25°C, 40°C, 50°C, and 60°C. The detection method is: place the deodorant sample in a constant temperature dry environment, and detect the weight loss rate of the sample at temperatures of 25°C, 40°C, 50°C, and 60°C for 30 minutes. The higher the weight loss rate, the faster the volatilization rate. Use a precision balance to measure the initial weight W0 of the capsule sample. After the experiment is carried out for 30 minutes, the measurement is ended and the final weight W30 is recorded. The weight loss rate = (W0-W30) / W0×100%. The detection results are shown in Table 2.

[0057] Table 2 Volatility test results of component B 25℃ 40℃ 50℃ 60℃ Example 1 ＜0.1% ＜0.1% 1-2% ＞4% Example 2 ＜0.1% ＜0.1% 1-2% 2-2.2% Example 3 ＜0.1% ＜0.1% 1-2% 2-2.2% Example 4 ＜0.1% ＜0.1% 1-2% 2-2.2% Comparative Example 1 ＜0.1% ＜0.1% 1-2% 2-2.2% Comparative Example 2 ＜0.1% ＜0.1% 2.2-2.5% 3-3.1% Comparative Example 3 ＜0.1% ＜0.1% ＜1% 1-2% Comparative Example 4 ＜0.1% ＜0.1% ＜1% ＜1% Comparative Example 5 ＜0.1% ＜0.1% ＜1% ＜1% Comparative Example 6 ＜0.1% ＜0.1% ＜1% ＜1% Comparative Example 7 1-2% 10-15% ＞20% ＞20% Comparative Example 8 ＜0.1% ＜0.1% ＜1% ＜1% Comparative Example 9 ＜0.1% ＜0.1% ＜1% ＜1% Comparative Example 10 ＜0.1% ＜0.1% 1-2% 2-2.2% Comparative Example 11 ＜0.1% ＜0.1% ＜1% ＜1% Comparative Example 12 ＜0.1% ＜0.1% ＜1% ＜1% Comparative Example 13 ＜0.1% ＜0.1% 1-2% 2-2.2% Comparative Example 14 ＜0.1% ＜0.1% 1-2% 2-2.2% In the present invention, component B is substantially non-volatile at 25° C., and the capsule structure has a good protective effect on component B. In the present invention, when the temperature exceeds 50° C., the volatilization rate of component B to which acrylic acid-modified poly-N-isopropylacrylamide is added is slower than that of component B to which acrylic acid-free poly-N-isopropylacrylamide is not added, and the excessive volatilization caused by excessively high temperature can be effectively avoided.

[0058] Test Example 3 The compressive strength of the capsule shell of component B in Examples 1 and 2 and Comparative Examples 3, 9, 10, 11 and 12 was tested. The testing method was the prior art. The test results are shown in Table 3.

[0059] Table 3 Compressive strength of capsule outer wall

[0060] The capsule of component B in the present invention has good compressive strength and meets the normal use and storage requirements of the capsule deodorant.

[0061] The above description is only a preferred embodiment of the present invention and is not intended to limit the scope of protection of the present invention. Any modifications, equivalent substitutions and improvements made by any technician familiar with the field within the spirit and principle of the present invention should be included in the scope of protection of the present invention.

Claims

1. An air deodorizer for an intensive care room, characterized in that: It comprises component A and component B, wherein the mass ratio of component A to component B is 1:1.7-2; the component A is a solid adsorption carrier, the component B is a capsule treatment agent, and the component B is evenly distributed on the component A; The component A comprises the following components in parts by weight: 100 parts of graphene-modified activated carbon, 50 parts of molecular sieve, and 5-6 parts of silane coupling agent; The shell of the capsule in component B comprises the following components in parts by weight: 50-52 parts of beeswax, 30 parts of glyceryl monostearate, 10 parts of polar-modified polyethylene, and 3-4 parts of nano-metal oxides; the inner core of the capsule comprises the following components in parts by weight: 60-70 parts of yucca extract modified by esterification of short-chain compounds, 80 parts of volatile solvents, 10 parts of propylene glycol, 5 parts of flavors, and 15 parts of xanthan gum.

2. The air deodorizer for an intensive care room according to claim 1, characterized in that: The short-chain compound esterified modified yucca extract is prepared by the following method: A1. Protecting active hydroxyl groups: dissolving the yucca extract in anhydrous pyridine, adding tert-butyldimethylsilyl chloride and 4-dimethylaminopyridine, stirring and reacting at room temperature for 12 hours, and after the reaction, purifying by column chromatography, eluting with an eluent, collecting fractions containing the protected yucca extract, and concentrating to obtain the protected yucca extract; wherein the ratio of the yucca extract to anhydrous pyridine is 1:10 g / ml, the mass ratio of tert-butyldimethylsilyl chloride to the yucca extract is 1.5:1, and the amount of 4-dimethylaminopyridine added is 5% of the mass of the yucca extract; B1. Esterification reaction: the protected yucca extract is mixed with glacial acetic acid and a small amount of concentrated sulfuric acid, heated and stirred in a 50°C oil bath for 6 hours and then cooled. After cooling, a saturated sodium carbonate solution is added to neutralize the excess acid until the solution is neutral; then extracted with ethyl acetate, the organic phase and the aqueous phase are separated, the organic phase is collected, dried with anhydrous sodium sulfate, filtered and concentrated to obtain a crude product; wherein the ratio of yucca extract to glacial acetic acid is 1:5 g / ml, and the ratio of yucca extract to concentrated sulfuric acid is 1:0.25 g / ml; C1. Deprotection: The crude product is dissolved in dichloromethane, tetrabutylammonium fluoride is added, and the mixture is stirred at room temperature for 4-6 hours. After the reaction is completed, the mixture is purified by column chromatography, and an eluent is used to elute the mixture, and the fractions containing the esterified modified yucca extract are collected and concentrated to obtain the esterified modified yucca extract of the short-chain compound; wherein the mass ratio of tetrabutylammonium fluoride to the crude product is 1.5:

1.

3. The air deodorizer for an intensive care room according to claim 1, characterized in that: The graphene-modified activated carbon is prepared by the following method: A2, adding graphene oxide powder to deionized water to prepare a dispersion of 5 mg / mL, and then subjecting the mixture to ultrasonic treatment for 60 minutes to obtain a graphene oxide dispersion; B2. Wash the activated carbon with deionized water and ethanol alternately and dry it at 60-80°C for later use; C2, adding the dried activated carbon to the graphene oxide dispersion, stirring and mixing, using ultrasonic treatment for 30 minutes and then standing for 12 hours, then filtering, washing and drying to obtain graphene oxide-coated activated carbon; D2, placing the activated carbon coated with graphene oxide in a tube furnace, introducing an inert gas, wherein the inert gas is N2 or Ar, excluding air, maintaining an inert atmosphere, heating to 900°C at a heating rate of 5-10°C / min, maintaining at 900°C for 1 hour, and naturally cooling to room temperature to obtain graphene-modified activated carbon; Wherein, in step C2, the mass ratio of graphene oxide to activated carbon is 1:

10.

4. The air deodorizer for an intensive care room according to claim 1, characterized in that: The volatile solvent includes ethyl acetate and ethanol, and the mass ratio of ethyl acetate to ethanol is 1:

2.

5. The air deodorizer for an intensive care room according to claim 1, characterized in that: The capsule shell in the component B also includes 20-22 parts of acrylic acid-modified poly-N-isopropylacrylamide, and the preparation method of the acrylic acid-modified poly-N-isopropylacrylamide is as follows: A3, dissolving N-isopropylacrylamide and acrylic acid in deionized water at a mass ratio of 9:1 to prepare a monomer solution; B3. Under stirring and heating, add 1% of ammonium persulfate by weight of the total monomer to the monomer solution, heat to 50°C and react for 1 hour, then add 0.5% of N,N'-methylenebisacrylamide by weight of the total monomer, heat to 60°C under nitrogen protection and react for 6 hours. After the reaction, purify and dry to obtain acrylic acid-modified poly (N-isopropylacrylamide).

6. The air deodorizer for an intensive care room according to claim 1, characterized in that: The nano metal oxide in the component B includes nano zinc oxide and nano aluminum oxide, and the mass ratio of nano zinc oxide to nano aluminum oxide is 1:

3.

7. The air deodorizer for an intensive care room according to claim 1, characterized in that: The molecular sieves in the component A include MCM-41 mesoporous molecular sieve, 13X zeolite molecular sieve and Beta zeolite, and the mass ratio of MCM-41 mesoporous molecular sieve, 13X zeolite molecular sieve and Beta zeolite is 1:2:

1.

8. The air deodorizer for an intensive care room according to claim 1, characterized in that: The polar modified polyethylene is a low-density linear polyethylene grafted with maleic anhydride.

9. The air deodorizer for an intensive care room according to claim 5, characterized in that: The component B is prepared by the following method: A4, adding beeswax, glyceryl monostearate and polar modified polyethylene into a reaction kettle, heating to 70-80° C., and stirring until completely melted to obtain a first intermediate; B4, adding nano metal oxide to the first intermediate, stirring evenly, to obtain a second intermediate; C4, dissolving acrylic acid-modified poly-N-isopropylacrylamide in an appropriate amount of deionized water, then adding N,N'-methylenebisacrylamide and ammonium persulfate, stirring evenly, adding the second intermediate, stirring evenly, heating to 70°C, reacting for 2 hours, cooling to 40°C after the reaction, keeping the liquid state, and obtaining a capsule shell material for standby use; wherein, the amount of N,N'-methylenebisacrylamide added is 0.5% of the mass of acrylic acid-modified poly-N-isopropylacrylamide, and the amount of ammonium persulfate added is 0.5% of the mass of acrylic acid-modified poly-N-isopropylacrylamide; D4, dissolving the yucca extract modified by esterification of short-chain compounds in a volatile solvent, adding propylene glycol, flavor and xanthan gum, and stirring evenly to form a uniform core solution; E4. Slowly add the inner core solution into the liquid capsule shell material, add an emulsifier, and emulsify using a high-speed shear emulsifier. During the emulsification process, the temperature is maintained at 50° C. After the emulsification is completed, cool at room temperature to obtain component B.

10. A method for preparing an air deodorant for an intensive care room according to any one of claims 1 to 9, characterized in that: The following steps are involved: S1. Preparation of component A: activating the molecular sieve at 200-300° C. for 2-3 hours to remove moisture and impurities; Dissolving a silane coupling agent in ethanol and stirring evenly to obtain a silane coupling agent solution; preparing graphene-modified activated carbon, and then mixing the graphene-modified activated carbon, the activated molecular sieve and the silane coupling agent solution, stirring evenly, and drying at 60-80° C. to obtain component A; S2. preparing component B using capsule preparation technology; S3. Spray the prepared component B evenly on the component A, stir and mix evenly, and then air-dry at room temperature for 2-3 hours to obtain the final air deodorant.

Images